# A Study to Learn More About Tukysa Once it is Out in the Korean Market

> **NCT06873191** · — · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 600 (estimated)

## Conditions studied

- HER2-positive Locally Advanced Unresectable
- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06873191
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873191, "A Study to Learn More About Tukysa Once it is Out in the Korean Market". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06873191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*